Unlike traditional methods that aim to eliminate cancer cells, a groundbreaking technology to reverse cancer cells into normal cells for treatment has been developed by a domestic research team.
The Korea Advanced Institute of Science and Technology (KAIST) announced on the 22nd that Professor Cho Kwang-Hyun’s team from the Department of Bio and Brain Engineering has developed a "reversible colorectal cancer treatment technology." This technology restores colorectal cancer cells to a state close to normal without destroying them, enabling treatment without side effects.
Currently, all anti-cancer therapies aim to kill cancer cells. However, this approach has fundamental limitations, such as cancer cells acquiring resistance and recurring or normal cells being destroyed in the process.
The research team focused on the fact that during the process of normal cells becoming cancerous, they regress along the normal trajectory of cell differentiation. They developed a technique to create a "digital twin" of the gene network that regulates the differentiation process of normal colorectal cells.
Through computer simulations, they identified the key target that inhibits the regression of the differentiation trajectory during the cancerization process of normal colorectal cells. By applying this target to colorectal cancer cells, they demonstrated through molecular and animal experiments that colorectal cancer cells can revert to normal colorectal cells.
This research lays the groundwork for cancer treatment by elucidating the reversible phenomenon of cancer cells returning to normal cells using the "digital twin" technology of cancer cell gene networks.
The achievement is highly regarded for showing the potential to develop reversible treatments applicable to various types of cancers.
The technology has been transferred to BioRevert Co., Ltd., which is advancing the development and commercialization of reversible cancer treatment drugs.
For Korean shopping and business agency services
Comments